CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

202292Orig1s000

LABELING

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use FULYZAQ safely and effectively. See full prescribing information for FULYZAQ.

 $FULYZAQ^{^{\rm TM}}$ (crofelemer) delayed-release tablets, for oral use Initial U.S. Approval: 2012

-----DOSAGE AND ADMINISTRATION------One 125 mg delayed-release tablet taken orally twice a day, with or without food (2)

-----DOSAGE FORMS AND STRENGTHS------Delayed-Release Tablets: 125 mg (3)

-----CONTRAINDICATIONS-----None. (4)

------WARNINGS AND PRECAUTIONS------Rule out infectious etiologies of diarrhea before starting crofelemer. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. (5.1)

CONTENTS*

- 1 INDICATIONS AND USAGE
- 2 DOSAGE AND ADMINISTRATION
- **3 DOSAGE FORMS AND STRENGTHS**
- 4 **CONTRAINDICATIONS**
- 5 WARNINGS AND PRECAUTIONS
 - 5.1 Risks of Treatment in Patients with Infectious Diarrhea
- 6 ADVERSE REACTIONS
 - 6.1 Clinical Trials Experience

7 DRUG INTERACTIONS

- 7.1 Drug Interaction Potential
- 7.2 Nelfinavir, Zidovudine, and Lamivudine
- 8 USE IN SPECIFIC POPULATIONS
 - 8.1 Pregnancy
 - 8.3 Nursing Mothers
 - 8.4 Pediatric Use
 - 8.5 Geriatric Use

To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-866-669-7597 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

-----USE IN SPECIFIC POPULATIONS------

- *Pregnancy* Based on animal data, may cause fetal harm (8.1) *Pediatric Use*: Safety and effectiveness of FULYZAQ has not
 - been established in patients less than 18 years of age (8.4)

See 17 for PATIENT COUNSELING INFORMATION

Revised: 12/2012

- 8.6 Use in Patients with Low CD4 Counts and High HIV Viral Load
- 10 OVERDOSAGE
- 11 DESCRIPTION
- 12 CLINICAL PHARMACOLOGY
 - 12.1 Mechanism of Action
 - 12.2 Pharmacodynamics
 - 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 13.2 Animal Toxicology and/or Pharmacology
- 14 CLINICAL STUDIES
- 15 REFERENCES
- 16 HOW SUPPLIED/STORAGE AND HANDLING
- **17 PATIENT COUNSELING INFORMATION**

*Sections or subsections omitted from the Full Prescribing Information are not listed.

1 FULL PRESCRIBING INFORMATION

2 1 **INDICATIONS AND USAGE**

3 FULYZAQ is indicated for symptomatic relief of non-infectious diarrhea in patients with 4 HIV/AIDS on anti-retroviral therapy.

5 2 DOSAGE AND ADMINISTRATION

6 The recommended dose of FULYZAQ is one 125 mg delayed-release tablet taken orally two 7 times a day, with or without food. FULYZAQ tablets should not be crushed or chewed. Tablets 8 should be swallowed whole.

9 3 **DOSAGE FORMS AND STRENGTHS**

10 FULYZAO is a white, oval, enteric-coated 125 mg delayed-release tablet printed on one side 11 with 125SLXP.

12 4 **CONTRAINDICATIONS**

13 None.

14 5 WARNINGS AND PRECAUTIONS

15 5.1 **Risks of Treatment in Patients with Infectious Diarrhea**

16 If infectious etiologies are not considered, and FULYZAQ is initiated based on a presumptive

17 diagnosis of non-infectious diarrhea, then there is a risk that patients with infectious etiologies 18 will not receive the appropriate treatments, and their disease may worsen. Before starting

19

FULYZAQ, rule out infectious etiologies of diarrhea. FULYZAQ is not indicated for the

20 treatment of infectious diarrhea.

21 6 **ADVERSE REACTIONS**

22 6.1 **Clinical Trials Experience**

23 Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials 24

- 25 of another drug and may not reflect the rates observed in practice.
- 26 A total of 696 HIV-positive patients in three placebo-controlled trials received FULYZAQ for a
- 27 mean duration of 78 days. Of the total population across the three trials, 229 patients received a
- 28 dose of 125 mg twice a day for a mean duration of 141 days, 69 patients received a dose of 250
- mg twice a day for a mean duration of 139 days, 102 patients received a dose of 250 mg four 29
- times a day for a mean duration of 14 days, 54 patients received a dose of 500 mg twice a day for 30

- a mean duration of 146 days, and 242 patients received a dose of 500 mg four times a day for a
- 32 mean duration of 14 days.
- 33 Adverse reactions for FULYZAQ that occurred in at least 2% of patients and at a higher
- 34 incidence than placebo are provided inTable 1.

Adverse Reaction	Crofelemer 125 mg BID* N = 229 n (%)	Placebo N = 274 n (%)	
Upper respiratory tract infection	13 (5.7)	4 (1.5)	
Bronchitis	9 (3.9)	0	
Cough	8 (3.5)	3 (1.1)	
Flatulence	7 (3.1)	3 (1.1)	
Increased bilirubin	7 (3.1)	3 (1.1)	
Nausea	6 (2.6)	4 (1.5)	
Back pain	6 (2.6)	4 (1.5)	
Arthralgia	6 (2.6)	0	
Urinary tract infection	5 (2.2)	2 (0.7)	
Nasopharyngitis	5 (2.2)	2 (0.7)	
Musculoskeletal pain	5 (2.2)	1 (0.4)	
Hemorrhoids	5 (2.2)	0	
Giardiasis	5 (2.2)	0	
Anxiety	5 (2.2)	1 (0.4)	
Increased alanine aminotransferase	5 (2.2)	3 (1.1)	
Abdominal distension	5 (2.2)	1 (0.4)	

35Table 1:Adverse Reactions Occurring in at Least 2% of Patients in the 125 mg36Twice Daily Group

* Twice daily

37 Adverse reactions that occurred in between 1% and 2% of patients taking a 250 mg daily dose of

38 FULYZAQ were abdominal pain, acne, increased aspartate aminotransferase, increased

39 conjugated bilirubin, increased unconjugated blood bilirubin, constipation, depression,

40 dermatitis, dizziness, dry mouth, dyspepsia, gastroenteritis, herpes zoster, nephrolithiasis, pain in

41 extremity, pollakiuria, procedural pain, seasonal allergy, sinusitis and decreased white blood cell

42 count.

43

44 Adverse reactions were similar in patients who received doses greater than 250 mg daily.

45 **7 DRUG INTERACTIONS**

46 **7.1 Drug Interaction Potential**

47

- 48 *In vitro* studies have shown that crofelemer has the potential to inhibit cytochrome P450
- 49 isoenzyme 3A and transporters MRP2 and OATP1A2 at concentrations expected in the gut. Due
- 50 to the minimal absorption of crofelemer, it is unlikely to inhibit cytochrome P450 isoenzymes
- 51 1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1 and CYP3A4 systemically [see Clinical Pharmacology
- 52 (12.3)].
- 53

54 7.2 Nelfinavir, Zidovudine, and Lamivudine

- 55 FULYZAQ administration did not have a clinically relevant interaction with nelfinavir,
- 56 zidovudine, or lamivudine in a drug-drug interaction trial.
- 57 8 USE IN SPECIFIC POPULATIONS
- 58 8.1 Pregnancy

59 Pregnancy Category C

60 Reproduction studies performed with crofelemer in rats at oral doses up to 177 times the

61 recommended daily human dose of 4.2 mg/kg revealed no evidence of impaired fertility or harm

- 62 to the fetus. In pregnant rabbits, crofelemer at an oral dose of about 96 times the recommended
- 63 daily human dose of 4.2 mg/kg, caused abortions and resorptions of fetuses. However, it is not
- 64 clear whether these effects are related to the maternal toxicity observed. A pre- and postnatal
- 65 development study performed with crofelemer in rats at oral doses of up to 177 times the
- recommended daily human dose of 4.2 mg/kg revealed no evidence of adverse pre- and postnatal
 effects in offspring. There are, however, no adequate, well-controlled studies in pregnant
- 68 women. Because animal reproduction studies are not always predictive of human response, this
- 69 drug should be used during pregnancy only if clearly needed.

70 8.3 Nursing Mothers

- 71 It is not known whether crofelemer is excreted in human milk. Because many drugs are excreted
- in human milk and because of the potential for adverse reactions in nursing infants from
- FULYZAQ, a decision should be made whether to discontinue nursing or to discontinue the
- 74 drug, taking into account the importance of the drug to the mother.

75 8.4 Pediatric Use

The safety and effectiveness of FULYZAQ have not been established in pediatric patients lessthan 18 years of age.

78 8.5 Geriatric Use

- 79 Clinical studies with crofelemer did not include sufficient numbers of patients aged 65 and over
- 80 to determine whether they respond differently than younger patients.

81 8.6 Use in Patients with Low CD4 Counts and High Viral Loads


- 82 No dose modifications are recommended with respect to CD4 cell count and HIV viral load,
- 83 based on the findings in subgroups of patients defined by CD4 cell count and HIV viral load.
- 84 The safety profile of crofelemer was similar in patients with baseline CD4 cell count less
- 85 than 404 cells/ μ L (lower limit of normal range) (N=388) and patients with baseline CD4 cell
- 86 counts greater than or equal to 404 cells/ μ L (N=289).
- 87 The safety profile of crofelemer was similar in patients with baseline HIV viral loads less
- than 400 copies/mL (N = 412) and patients with baseline HIV viral loads greater than or equal to 100
- 89 400 copies/mL (N = 278).

90 10 OVERDOSAGE

91 There has been no reported experience with overdosage of crofelemer.

92 11 DESCRIPTION

- 93 FULYZAQ (crofelemer) delayed-release tablets is an anti-diarrheal, enteric-coated drug product
- 94 for oral administration. It contains 125 mg of crofelemer, a botanical drug substance that is
- 95 derived from the red latex of *Croton lechleri* Müll. Arg. Crofelemer is an oligomeric
- 96 proanthocyanidin mixture primarily composed of (+)-catechin, (-)-epicatechin, (+)-gallocatechin,
- 97 and (-)-epigallocatechin monomer units linked in random sequence, as represented below. The
- average degree of polymerization for the oligomers ranges between 5 and 7.5, as determined by
- 99 phloroglucinol degradation.



100

- 101 Inactive ingredients: microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide,
- 102 and magnesium stearate.

- 103 Coating ingredients: ethylacrylate and methylacrylate copolymer dispersion, talc, triethyl citrate,
- and white dispersion which contains xanthan gum, titanium idoxide, propyl paraben, and methyl
- 105 paraben.
- 106

107 12 CLINICAL PHARMACOLOGY

108 12.1 Mechanism of Action

- 109 Crofelemer is an inhibitor of both the cyclic adenosine monophosphate (cAMP)-stimulated
- 110 cystic fibrosis transmembrane conductance regulator (CFTR) chloride ion (Cl⁻) channel, and the
- 111 calcium-activated Cl⁻ channels (CaCC) at the luminal membrane of enterocytes. The CFTR Cl⁻
- 112 channel and CaCC regulate Cl⁻ and fluid secretion by intestinal epithelial cells. Crofelemer acts
- 113 by blocking Cl⁻ secretion and accompanying high volume water loss in diarrhea, normalizing the
- 114 flow of Cl⁻ and water in the GI tract.

115 **12.2 Pharmacodynamics**

- 116 Consistent with the mechanism of action of crofelemer (i.e., inhibition of CFTR and CaCC in the
- 117 GI lumen), data suggest stool chloride concentrations decreased in patients treated with
- 118 FULYZAQ (500 mg four times daily) (n=25) for four days relative to placebo (n=24); stool
- 119 chloride concentrations decreased in both African American patients treated with FULYZAQ
- 120 (n=3) relative to placebo (n=5) and non-African American patients treated with FULYZAQ
- 121 (n=22) relative to placebo (n=19).
- 122 At a dose 10 times the maximum recommended dose, crofelemer does not prolong the QTc
- 123 interval to any clinically relevant extent.

124 **12.3 Pharmacokinetics**

125 Absorption

- 126 The absorption of crofelemer is minimal following oral dosing in healthy adults and
- 127 HIV-positive patients and concentrations of crofelemer in plasma are below the level of
- 128 quantitation (50 ng/mL). Therefore, standard pharmacokinetic parameters such as area under the
- 129 curve, maximum concentration, and half-life cannot be estimated.
- 130 Distribution
- 131 The distribution of crofelemer has not been determined.
- 132 Metabolism
- 133 No metabolites of crofelemer have been identified in healthy subjects or patients in clinical trials.

134 Elimination

- 135 The elimination route has not been identified in humans.
- 136 Food Effect
- 137 Administration of crofelemer with a high-fat meal was not associated with an increase in
- 138 systemic exposure of crofelemer in healthy volunteers. In the clinical trial, a single 500 mg dose
- 139 of crofelemer was administered one-half hour before the morning and evening meals. Therefore,
- 140 crofelemer may be administered with or without a meal.

141 Drug-Drug Interactions

- 142 Results of a crossover study in healthy volunteers showed crofelemer 500 mg administered four
- 143 times daily for five days had no effect on the exposure of zidovudine and nelfinavir when
- administered as a single dose. A 20% decrease in lamivudine exposure was also observed in the
- same study but was not considered to be clinically important.

14613NONCLINICAL TOXICOLOGY

147 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

- 148 Carcinogenesis
- Long-term studies in animals have not been performed to evaluate the carcinogenic potential ofcrofelemer.
- 151 Mutagenesis
- 152 Crofelemer was negative in the bacterial reverse mutation assay, chromosomal aberration assay,153 and rat bone marrow micronucleus assay.
- 154 Impairment of Fertility
- 155 Crofelemer, at oral doses of up to 738 mg/kg/day (177 times the recommended human daily dose 156 of 4.2 mg/kg), had no effects on fertility or reproductive performance of male and female rats.

157 14 CLINICAL STUDIES

- 158 The efficacy of FULYZAQ 125 mg delayed-release tablets twice daily was evaluated in a
- randomized, double-blind, placebo-controlled (one month) and placebo-free (five month), multi-
- 160 center study. The study enrolled 374 HIV-positive patients on stable anti-retroviral therapy
- 161 (ART) with a history of diarrhea for one month or more. Diarrhea was defined as either
- 162 persistently loose stools despite regular use of anti-diarrheal medication (ADM) (e.g.,
- 163 loperamide, diphenoxylate, and bismuth subsalicylate) or one or more watery bowel movements
- 164 per day without regular ADM use.

- 165 Patients were excluded if they had a positive gastrointestinal (GI) biopsy, GI culture, or stool test
- 166 for multiple bacteria (*Salmonella*, *Shigella*, *Campylobacter*, *Yersinia*, *Mycobacterium*), bacterial
- 167 toxin (*Clostridium difficile*), ova and parasites (*Giardia, Entamoeba, Isospora, Cyclospora,*
- 168 Cryptosporidium, Microsporidium), or viruses (Cytomegalovirus). Patients were also excluded
- 169 if they had a history of ulcerative colitis, Crohn's disease, celiac sprue (gluten-enteropathy),
- 170 chronic pancreatitis, malabsorption, or any other GI disease associated with diarrhea.

171 The study had a two-stage adaptive design. In both stages, patients received placebo for 10 days

- 172 (screening period) followed by randomization to crofelemer or placebo for 31 days of treatment
- 173 (double-blind period). Only patients with 1 or more watery bowel movements per day on at least
- 174 5 of the last 7 days in the screening period were randomized to the double-blind period. Each
- 175 stage enrolled patients separately; the dose for the second stage was selected based on an interim
- analysis of data from the first stage. In the first stage, patients were randomized 1:1:1:1 to one of
- three crofelemer dose regimens (125, 250, or 500 mg twice daily) or placebo. In the second
- stage, patients were randomized 1:1 to crofelemer 125 mg twice daily or placebo. The efficacy
- analysis was based on results from the double-blind portion of both stages.
- 180 Each study stage also had a five month period (placebo-free period) that followed the double-
- 181 blind period. Patients treated with crofelemer continued the same dose in the placebo-free
- 182 period. In the first stage, patients that received placebo were re-randomized 1:1:1 to one of the
- 183 three crofelemer dose regimens (125, 250, or 500 mg twice daily) in the placebo-free period. In
- the second stage, patients that received placebo were treated with crofelemer 125 mg twice daily
- 185 in the placebo-free period.
- 186 The median time since diagnosis of HIV was 12 years. The percentage of patients with a CD4
- 187 cell count of less than 404 was 39%. The percentage of patients with a HIV viral load greater
- than or equal to 1000, 400 to 999, and less than 400 HIV copies/mL was 7%, 3%, and 9%,
- respectively; the remainder had a viral load that was not detectable. The median time since
- diarrhea started was 4 years. The median number of daily watery bowel movements was 2.5 per
- 191 day.
- 192 Most patients were male (85%). The percentage of patients that were Caucasian was 46%; the
- percentage of patients were male (85%). The percentage of patients that were Caucasian was 46%, the
 percentage of patients that were African-American was 32%. The median age was 45 years with
 a range of 21 to 68 years.
- 195 In the double-blind period of the study, 136 patients received crofelemer 125 mg twice daily, 54
- 196 patients received 250 mg twice daily, 47 patients received 500 mg twice daily, and 138 patients
- 197 received placebo. The percentages of patients that completed the double-blind period were 92%,
- 198 100%, 85%, and 94% in the 125 mg, 250 mg, 500 mg, and placebo arms, respectively.
- 199 Most patients received concomitant protease inhibitors (PI) during the double-blind period
- 200 (Table 2). The most frequently used ARTs in each group were tenofovir/emtricitabine, ritonavir, 201 and lopinavir/ritonavir
- and lopinavir/ritonavir.

202 Table 2: **Concomitant ART Use in the Double-Blind Period**

	125 mg BID (N = 136)	250 mg BID (N = 54) n (%)	500 mg BID (N = 46) n (%)	Placebo BID (N = 138) n (%)
	n (%)			
Any ART	135 (99)	53 (98)	45 (98)	134 (97)
Any PI	87 (64)	41 (76)	33 (72)	97 (70)
Tenofovir/Emtricitabine	45 (33)	22 (41)	16 (35)	52 (38)
Ritonavir	46 (34)	18 (33)	15 (33)	49 (36)
Lopinavir/Ritonavir	30 (22)	21 (39)	15 (33)	40 (29)
Efavirenz/Tenofovir/ Emtricitabine	30 (22)	7 (13)	7 (15)	21 (15)
Tenofovir disoproxil fumarate	18 (13)	8 (15)	5 (11)	14 (10)
Antazanavir sulfate	19 (14)	3 (6)	6 (13)	22 (16)
Abacavir w/ lamivudine	17 (13)	5 (9)	5 (11)	18 (13)
Darunavir	19 (14)	4 (7)	4 (9)	14 (10)
Raltegravir	16 (12)	4 (7)	5 (11)	11 (8)
Valaciclovir hydrochloride	12 (9)	8 (15)	5 (11)	16 (12)
Fosamprenavir	12 (9)	6 (11)	4 (9)	13 (9)
Zidovudine w/ lamivudine	12 (9)	3 (6)	3 (7)	15 (11)
Lamivudine	7 (5)	6(11)	4 (9)	6 (4)
Nevirapine	8 (6)	6 (11)	3 (7)	9 (7)
Atazanavir	5 (4)	6(11)	2 (4)	2 (1)

203 204 Abbreviations: ART = antiretroviral therapy; PI = Protease Inhibitor; BID = twice daily.

* greater than 10% of Any Treatment Group

205 The primary efficacy endpoint was the proportion of patients with a clinical response, defined as

206 less than or equal to 2 watery bowel movements per week during at least 2 of the 4 weeks of the 207 placebo-controlled phase. Patients who received concomitant ADMs or opiates were counted as

clinical non-responders. 208

209 A significantly larger proportion of patients in the crofelemer 125 mg twice daily group

experienced clinical response compared with patients in the placebo group (17.6% vs. 8.0%, 210

1-sided p < 0.01). 211

212 In the randomized clinical study, examination of duration of diarrhea, baseline number of daily

- watery bowel movements, use of protease inhibitors, CD4 cell count and age subgroups did not 213
- 214 identify differences in the consistency of the crofelemer treatment effect among these subgroups.
- 215 There were too few female subjects and subjects with an HIV viral load > 400 copies/mL to
- adequately assess differences in effects in these populations. Among race subgroups, there were 216
- no differences in the consistency of the crofelemer treatment effect except for the subgroup of 217

African-Americans: crofelemer was less effective in African-Americans than non-African-218

219 Americans.

220 Although the CD4 cell count and HIV viral load did not appear to change over the one month

- 221 placebo-controlled period, the clinical significance of this finding is unknown because of the
- 222 short duration of the placebo-controlled period.
- 223 Of the 24 clinical responders to crofelemer (125 mg twice daily), 22 entered the placebo-free
- 224 period; 16 were responding at the end of month 3, and 14 were responding at the end of month 5.

225

226 **15 REFERENCES**

227 16 HOW SUPPLIED/STORAGE AND HANDLING

- Crofelemer delayed-release tablets, 125 mg, are white, oval enteric-coated tablets printed on one
 side with 125SLXP. They are available in the following package size:
- 230 Bottles of 60: NDC 65649-802-02

231 Store at 20°C-25°C (68°F-77°F); excursions permitted between 15°C-30°C (59°F-86°F). See

232 USP Controlled Room Temperature.

233 17 PATIENT COUNSELING INFORMATION

- Instruct patients that FULYZAQ tablets may be taken with or without food.
- Instruct patients that FULYZAQ tablets should not be crushed or chewed. Tablets
 should be swallowed whole.
- Manufactured for Salix Pharmaceuticals, Inc., Raleigh, NC 27615 by Patheon, Inc. FULYZAQ
 is distributed by Salix Pharmaceuticals, Inc. under license from Napo Pharmaceuticals, Inc.

The botanical drug substance of FULYZAQ is extracted from *Croton lechleri* (the botanical raw material) that is harvested from the wild in South America.

- 241 Copyright © Salix Pharmaceuticals, Inc.
- 242 US Patent Nos. 7,341,744 and 7,323,195.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JULIE G BEITZ 12/31/2012